MLN undiluted NAV as at 10/5/22 - $0.9264

MKTUPDTE
Thu, May 12 2022 02:28 pm

MLN undiluted NAV as at 10/5/22 - $0.9264

Date 10/5/2022 3/5/2022
MLN undiluted NAV $0.9264 $1.0012
Share price close $1.16 $1.18
(Premium) (25%) (18%)


The above net asset value (NAV) is unaudited and net of fees and tax.

The NAV per share is calculated after deducting treasury stock (shares acquired under the Marlin Global buyback programme) - currently nil.

* The undiluted NAV excludes any impact on the NAV of the future exercise of warrants (MLNWE). At 10 May 2022, 47,256,870 warrants are on issue and may be exercised on 20 May 2022. The final exercise price of each warrant is $1.18.

The five largest portfolio holdings at 10 May 2022 are approximately as follows:

Meta Platforms 10%
Alphabet 7%
PayPal 6%
Tencent 6%
Alibaba Group 6%


BACKGROUND
Marlin Global is a listed investment company that invests in growing companies based outside of New Zealand and Australia. The Marlin portfolio is managed by Fisher Funds, a specialist investment manager with a track record of successfully investing in growth company shares. The aim of Marlin is to offer investors competitive returns through capital growth and dividends, and access to a diversified portfolio of investments through a single, tax-efficient investment vehicle. Marlin listed on the NZX Main Board on 1 November 2007 and may invest in companies that are listed on any approved stock exchange (excluding New Zealand or Australia) or unlisted companies not incorporated in New Zealand or Australia.

Contact
Corporate Manager
Marlin Global Limited
Tel +64 9 4840352


Announcement PDF


Markets News

Fisher & Paykel Healthcare helps NZX up 1%
Markets Market Close

Fisher & Paykel Healthcare helps NZX up 1%

Skellerup Holdings shares rose 5.1%. 

Retail

Warehouse drops guidance, loss now in scope

The retailer has raised the possibility of a full-year earnings loss.

Warehouse drops guidance, loss now in scope
Markets Analysis

Xero’s Melio ‘leap of faith’

The NZ-founded company’s giant-killer dreams in the US hinge on this huge bet. 

Xero’s Melio ‘leap of faith’